Pulmonary function tests in patients with LAM over time.

<p>Pulmonary function tests in patients with LAM over time.</p

Time to renal angiomyolipoma progression.

<p>Time to renal angiomyolipoma progression.</p

Median GFR (A) and creatinine (B) over time.

<p>Medians are connected by lines, means are displayed as dots. Boxes are drawn from P25 to P75. Whiskers extend from P10 to P90. # indicates values that lie outside [P10, P90]. *Baseline assessment is the last performed before start of everolimus. Post-baseline laboratory assessments performed at unplanned schedule or more than 28 days after discontinuation of everolimus are not presented. Only results from central laboratory are included. Abbreviations: BL = baseline; GFR = glomerular filtration rate; P = percentile.</p

Renal angiomyolipoma response rate with everolimus over time.

<p>Renal angiomyolipoma response rate with everolimus over time.</p

Reduction in SEGA volume with everolimus over time in patients with renal angiomyolipomas.

<p>Reduction in SEGA volume with everolimus over time in patients with renal angiomyolipomas.</p

Patient baseline characteristics.

<p>Patient baseline characteristics.</p

Adverse events by preferred term regardless of relationship to study drug and by year of emergence (>15% of patients).

<p>Adverse events by preferred term regardless of relationship to study drug and by year of emergence (>15% of patients).</p

CONSORT flow diagram of patient disposition in the double-blind followed by open-label periods.

<p>^aPatients with angiomyolipoma progression were unblinded at the end of the double-blind phase, and patients who were on placebo were allowed to cross over to open-label everolimus.</p

Proportion of patients with ≥50% reduction/improvement in SEGA, renal angiomyolipoma, or skin lesions.

<p>* *Skin lesion response determined as partial or complete by Physician’s Global Assessment.</p

CONSORT diagram.

<p>*Administrative problems defined as non-compliant with study visit or non-compliant with study drug.</p